Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 2233-2240

  Ackerman, Margaret E ^a   Pawlowski, David ^c   Wittrup, K Dane ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c Case Western Reserve University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A33 ANTIBODY; ANTIBODY; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; UNCLASSIFIED DRUG; CANCER ANTIBODY; TUMOR ANTIGEN;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; COMPARATIVE STUDY; DRUG PENETRATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR SPHEROID; TURNOVER TIME; CELL CULTURE; ENDOCYTOSIS; HUMAN; METABOLISM; MULTICELLULAR SPHEROID;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ENDOCYTOSIS; HUMANS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 51049105989     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0067     Document Type: Article

References (30)

1. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007;109:170-9.
2. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
3. Jain RK. Transport ofmolecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63.
4. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007;48:995-9.
5. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003;63:1288-96.
6. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. In press. 2007.
7. van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences ofa "binding site barrier." Cancer Res 1991;51:4776-84.
8. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5.
9. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007;67:254-61.
10. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 1986;46:3969-78.
11. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998;42:225-41.
12. Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277:35035-43.
13. Kenanova V, Olafsen T, Crow DM, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anticarcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005;65:622-31.
14. Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence ofan IgG fragment by random mutagenesis. Nat Biotechnol 1997;15:637-40.
15. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A 1999;96:3137-42.
16. Ackerman ME, Chalouni C, Raman VV, et al. A33 antigen displays persistent surface expression. Cancer Immunol Immunother 2008;57:1017-27.
17. Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety ofcell types. Biotechnol Bioeng 2003;83:173-80.
18. Sutherland RM, Durand RE. Radiation response of multicell spheroids-an in vitro tumour model. Curr Top Radiat Res Q 1976;11:87-139.
19. Pluen A, Boucher Y, Ramanujan S, et al. Role oftumor- host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001;98:4628-33.
20. Saga T, Neumann RD, Heya T, et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A 1995;92:8999-9003.
21. Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 1990;8:1894-906.
22. Scott AM, Lee FT, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11:4810-7.
23. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update ofcar cinoembryonic antigen radioimmunotherapy with (131)ilabetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007;14:2577-90.
24. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981;41:4354-60.
25. Begent RH, Verhaar MJ, Chester KA, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-84.
26. Jang SH, Wientjes MG, Au JL. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 2001;296:1035-42.
27. Brouwers AH, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm 2003;18:539-47.
28. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Huntingt) 2005;19:7-16.
29. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007;67:10664-8.
30. McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006;66:2509-13.